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6Vascular access outcomes in hemodialysis are critically important for patients and clinicians, but
frequently are neither patient relevant nor measured consistently in randomized trials. A Standardized
Outcomes in Nephrology–Hemodialysis (SONG-HD) consensus workshop was convened to discuss
the development of a core outcome measure for vascular access. 13 patients/caregivers and 46
professionals (clinicians, policy makers, industry representatives, and researchers) attended. Partici-
pants advocated for vascular access function to be a core outcome based on the broad applicability of
function regardless of access type, involvement of a multidisciplinary team in achieving a functioning
access, and the impact of access function on quality of life, survival, and other access-related out-
comes. A core outcome measure for vascular access required demonstrable feasibility for imple-
mentation across different clinical and trial settings. Participants advocated for a practical and ﬂexible
outcome measure with a simple actionable deﬁnition. Integrating patients’ values and preferences was
warranted to enhance the relevance of the measure. Proposed outcome measures for function
included “uninterrupted use of the access without the need for interventions” and “ability to receive
prescribed dialysis,” but not “access blood ﬂow,” which was deemed too expensive and unreliable.
These recommendations will inform the deﬁnition and implementation of a core outcome measure for
vascular access function in hemodialysis trials.Background
A functioning vascular access is a lifeline for patients
requiring hemodialysis (HD), but has a high risk of
complications.1 Vascular access complications account for
approximately 20% to 30% of hospital admissions for
patients on HD and incur substantial health care costs.2,3
One in every 2 arteriovenous fistulas or grafts will fail to
function within the first year of creation and necessitate
further interventions for problems such as inadequate
maturation, stenosis, or thrombosis.4-7 Central venous
catheters are often required and may be associated with
even higher levels of morbidity, mortality, and health care
costs.8,9 Infection, bleeding, and pain during arteriovenous
access (fistula or graft) cannulation can cause further stress
to patients and their caregivers.10,11 Improving vascular
access outcomes is therefore a critical priority for patients
requiring HD, their caregivers, and clinicians.12
Many trials have been conducted in an effort to improve
vascular access outcomes, but little success has been
achieved.5,13,14 The interpretation and applicability of trial
outcomes are limited by the extreme heterogeneity of
reported outcome measures, use of outcomes that may
not be directly relevant to patients or clinical decision mak-
ing, and outcome reporting bias.15 The ability to assess the
comparative effects of interventions on vascular access com-
plications has been limited by inconsistent outcome report-
ing.4,14,16,17 The need to standardize reporting of critically
important outcomes has been widely advocated,18-21 and90there is a growing number of initiatives to establish core
outcome sets, defined as an agreed-upon minimum set of
standardized outcomes that ought to be measured and
reported in all trials for a specific clinical area.22-26
The international Standardized Outcomes in
Nephrology (SONG) initiative aims to establish a set of
core outcome measures across the spectrum of chronic
kidney disease based on the shared priorities of patients,
caregivers, clinicians, researchers, policy makers, and in-
dustry. Consistent reporting of highly relevant core out-
comes in clinical trials can help improve the quality,
relevance, and comparability of research to inform clinical
decision making, inform quality improvement initiatives,
and help facilitate measurement of clinical outcomes in
everyday practice. The first and current focus of SONG is
on establishing a set of core outcomes for HD following
established methodology.12,15,23,26,27 Based on consensus
among 1,200 patients, caregivers, and health professionals
from more than 70 countries, vascular access has been
identified as 1 of 4 core outcome domains in HD
(ie, vascular access, fatigue, cardiovascular disease, and
mortality).12,28 The current report focuses on the devel-
opment of a core outcome measure for vascular access.
The aim of this workshop report is to describe and
summarize stakeholder perspectives on the identification
and implementation of a core outcome measure for
vascular access to be used across all HD trials. This will help
ensure that the most relevant and meaningful outcomeAJKD Vol 71 | Iss 5 | May 2018
Special Reportmeasure is selected, address potential challenges, and
optimize implementation strategies.SONG-HD Vascular Access Consensus
Workshop
Context and Scope
The international SONG-HD vascular access consensus
workshop was convened in Chicago during the American
Society of Nephrology Kidney Week Conference in 2016
for stakeholders to discuss the identification and imple-
mentation of a core outcome measure for vascular access to
be reported in all trials in HD. The top prioritized out-
comes were vascular access function and infection based
on a systematic review and interim results from an inter-
national survey on vascular access outcomes that was
completed by patients/caregivers and health professionals.
Participants and Contributors
Patients, caregivers, and health professionals (nephrolo-
gists, radiologists, interventionalists, surgeons, nursing
and allied health professionals, researchers, and policy
makers) with current or previous experience with HD
were invited to the workshop. To further enhance suc-
cessful dissemination and implementation of the vascular
access core outcome measure, invitations were extended to
representatives of professional societies (eg, American
Society of Nephrology, Australian and New Zealand Soci-
ety of Nephrology, European Society of Nephrology, and
the Asian Pacific Society of Nephrology), regulatory
agencies (eg, US Food and Drug Administration and
Centers for Medicare & Medicaid Services), nephrology
journals, registries, funding organizations (eg, US National
Institutes for Health), industry, and guideline organiza-
tions (eg, KDIGO [Kidney Disease: Improving Global
Outcomes]). In total, 59 participants (11 patients, 2
caregivers, and 46 health professionals) from 12 countries
attended the workshop and 25 workshop contributors
provided feedback on the workshop materials and pre-
liminary report, but were unable to attend the workshop in
person (Table S1). All workshop participants consented to
being recorded and listed as investigators and ethics
approval was therefore not required for this workshop.
Workshop Program and Materials
The 2-hour workshop was held on November 18, 2016, at
Conference Chicago at University Center in Chicago, IL. The
workshop program, background material (including exam-
ples of outcome measures and validation tools29), and
interim results were sent to participants 2 weeks in advance.
During theworkshop, an overviewof the SONG-HDVascular
Access Initiative was presented, including interim results
from the aforementioned systematic review of vascular access
outcome measures and the SONG-HD vascular access survey.
Participants were allocated to 1 of 5 breakout discussion
groups. Each group had 10 to 13 members and included 2
to 4 patients or caregivers and at least 1 member of theAJKD Vol 71 | Iss 5 | May 2018SONG-HD vascular access working group. The facilitator of
each group (C.M.H., A.K.V., B.M., A.T., and E.O.) received a
briefing session before theworkshop andwas providedwith
a question guide (Item S1). Participants discussed the
interim results of the survey (which will be reported sepa-
rately but are referred to in this report when necessary to
provide context for specific statements), potential core
outcomes (ie, function and infection), and outcome
measures. Examples of outcome measures, measurement
properties, and feasibility aspects for the selection of a core
outcome measure29 were provided as prompts. Participants
were also asked to discuss strategies for implementing
core outcomemeasures in trials. In the final plenary session,
all groups reconvened and a member from each group
presented key points from their discussion, which was then
summarized by the chair of the workshop (C.M.H.).
All breakout and plenary discussions were audiotaped
and transcribed. The transcripts were entered into Hyper-
RESEARCH (ResearchWare Inc; version 3.0.) to facilitate
coding and data analysis. From the transcripts, A.K.V.
reviewed and analyzed participants’ comments and sug-
gestions regarding the development and implementation
of a core outcome measure for vascular access in HD.
Following the workshop, all participants and contributors
received a draft workshop report to provide feedback
within a 2-week time frame. Additional comments were
integrated into the final report.Summary of Workshop Discussion
Overall, we identified 5 themes from the discussion: (1)
capturing the broad applicability of function, (2) emphasizing
experiential relevance and severity, (3) demonstrating feasi-
bility of implementation, (4) ensuring robustness and validity,
and (5) integrating patients’ values and preferences. Illustrative
quotations for each theme are shown in Box 1 and contribu-
tions from breakout groups to the respective themes are listed
in Table S2. Possible outcome measures discussed during the
workshop are provided in Table 1, and recommendations of
the consensus workshop are summarized in Box 2.
Capturing the Broad Applicability of Function
Applicable to All Access Types
Function was confirmed by workshop participants to be the
most important vascular access outcome, reflecting interim
results of the international survey. Participants emphasized
that access function was equally relevant to all access types
(ie, fistula, graft, and central venous catheter) and contrib-
uted greatly to the success of HD. In comparison, although
infection was commonly encountered in catheters, it was
less so in grafts and fistulas. Therefore, as one health pro-
fessional put it, “by focusing on infection we will
completelymiss the boat if we are looking at the full scope of
access.” Similarly, although cannulation problems were
considered a very important outcome by patients and health
professionals, this applied only to fistulas and grafts and was
therefore deemed unsuitable as a core outcome. Participants691
Box 1. Selected Quotations From the Workshop Discussions on the Identiﬁcation and Implementation of a Vascular Access Core
Outcome Measure in Hemodialysis
Theme: Capturing the Broad Applicability of Function
Applicable to all access types
• “I was just going to say function is a good one, because it has to apply to all types of access, which function clearly does. It has to
be important. It was important in the survey.” -H2
• “Cannulation would be a very important outcome to assess when we get to vascular access speciﬁc trials, so some trials that only
address ﬁstulas and grafts where cannulation actually plays an important and crucial role. If we look at all dialysis trials, where
catheters don’t have to be cannulated, for example, that may be the reason why this didn’t come up as the core outcome, the
most important one.” -H2
• “If you look at the three access types that are used for chronic dialysis, function is the only one that’s applicable overwhelmingly to
all, because we know that infection is most prominent in catheters, minimal in ﬁstulas, and then somewhere in between for grafts
but not to the degree that it is for catheters. So by focusing on infection we’ll completely miss the boat if we’re looking at the full
scope of access.” -H5
Multidisciplinary involvement
• “And when I look at function, it’s not just the surgeon that puts it in. It’s not just the patient. It’s the entire team. It’s the doctor, it’s
the nurse, it’s the technician; it’s everybody that’s involved in that patient’s care. So I want to make sure our prime measure gives
us a chance to look at the entire team that’s taking care of that patient.” -H5
Contributing to quality of life
• “Keeping the access open is giving you a better quality of life and why wouldn’t they want to do that.” -P1
• “That [a functioning access] means to me that I’m getting good health.” -P1
• “What the patients brought up which is very crucial is this concept in terms of function, the maintenance of life versus quality of life
so you could have poor function but it’s maintaining life but, I think, you need to balance that with quality of life and how many
interventions were they having?” -H1
• “I have one word and that’s just the health of the patient…That’s the most important thing, the function of that ﬁstula.” -P4
Capturing important multidimensional aspects
• “The intervention is also incorporated into interfering with activity, so having that extra visit to the hospital was part of interfering
with your daily life and activity so it, kind of, also got incorporated into that.” -H1
• “When you’re talking about function, it incorporates to some degree cannulation and many other aspects of function, so as a
global aggregate outcome measure; it captures elements of a number of things that are quite important to everybody.” -H2
Preventing subsequent consequences
• “The ﬁrst thing that you want is for the ﬁstula to function properly because if it doesn’t function properly you’re in pain and then you
have to go get it redone again and you have to have that catheter stuck back in you and then you run the risk of infection with a
catheter in.” -P4
• “I’m not surprised that function and infection are the top two because when you have issues in those two areas it leads to
increased events like hospitalizations, more interaction with the health care facility than you might want, more procedures.” -H4
• “[Function is the most important outcome] just because of problems that arise as far as the function is concerned.” -P5
Theme: Emphasizing Experiential Relevance and Severity
Variability in experiences
• “The priority, because of the experience I’ve had from August until now, has been the cannulation, the needling, and to me, the
experience has not been good.” -P2
• “The issue was for people who hadn’t experienced aneurysms and other things, how do you relate to that? (…) So it’s hard to rate
something from one to nine if you haven’t experienced it, or didn’t have any sense of how it could happen.” -P3
• “If you don’t know what steal is you might not rank it very high, but I think it has a terrible outcome which is very important to
avoid.” -H4
• “I just wondered about steal: if people are thinking of a mild form then it will get a very different result. When I think of steal I think
of severe steal.” -H4
Fear-driven prioritization
• “…Those needles are a fear thing.” -P2
• “There’s a lot of anxiety around potential for infection.” -C3
• “He, as my caregiver, worries more that he’d be responsible for infection. And I worry less about that, I worry more about ex-
plosions [rupture of an aneurysm]. Well those sorts of things just scare me.” -P3
Theme: Demonstrating Feasibility of Implementation
Simple, requiring minimal resources
• “In terms of function I would say blood ﬂow rates, because it’s easily measurable, everyone understands it, and you can track it
very easily.” -H3
• “I wouldn’t use blood ﬂow rate at all. I would just use a simple deﬁnition about being able to use the access for dialysis without
interruption or problems because it’s simple, it covers both, catheters, grafts and ﬁstulas.” -H3
(Continued)
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Box 1 (Cont'd). Selected Quotations From the Workshop Discussions on the Identiﬁcation and Implementation of a Vascular
Access Core Outcome Measure in Hemodialysis
• “One of the keys is simplicity. If it’s very simple, then both patients can measure it easily, can relate to it, and also the units can
document very simply as well. A good [counter-]example is measuring blood ﬂow. It requires specialized equipment. It’s out for
home dialysis, unless you pay for someone to go there and do it. A lot of units can’t afford to buy that machine, and don’t use it.
Something that’s simple, easy to use, is key.” -H3
• “We think about this in the context of trials and studies and ease of measurement in its study, but the extension of that is that we’ll
often use for quality improvement and accountability, so how are we doing in day to day life? And that measure has to be
something that is easily implementable in everyday practice and easy to measure so you don’t end up waiting to come off the
machine any longer than you need to.” -H2
Pragmatic deﬁnition
• “…Having a robustly pragmatic deﬁnition is much, much easier and perhaps more meaningful than a certain number of can-
nulations or a certain number of mLs per minute ﬂow related deﬁnition of access function.” -H4
• “Whether or not you can do somebody’s standard dialysis, or standard prescribed dialysis treatment using the access or not.
That’s a good deﬁnition that would ﬁt all access types, and really just encompass the functionality aspect.” -H3
• “What do you do about the marginal one that is still going but has extended dialysis duration to reduce ﬂow rates? As a clinical
pragmatist I would say that’s functional because we’re getting by and we’ve chosen to accept that because the balance is—that’s
a better outcome than sticking a line back in. That’s a very pragmatic deﬁnition.” -H4
• “You have to be clear about what you consider to be the prescribed dialysis and you have to be clear on what’s an intervention,
and whether you have an intervention or not, and that has to be recorded in order to answer that question. It’s a great idea, to have
a tick box, and in itself, it’s still an easy way to assess an outcome. It doesn’t take any extra equipment.” –H2
Practicality across settings internationally
• “Across cultures, we do consider adequate dialysis differently. By leaving it at the prescribed dialysis, you leave it up to the actual
center or country.” -H2
• “In the eyes of the clinician and the patient, functioning enough to not have to intervene? And that’s going to be a little bit different
for different people around the world.” -H5
• “Some units operate, they like 400 mL/min ﬂows. There are units in, particularly Asia, where they’re quite happy with 200 mL/min.”
-H5
• “What if we’re trying to do a universal measure and a lot of places don’t use ultrasound?” -H5
Flexibility for different trial settings
• “It’s nice to have one core coherent deﬁnition, but for trials evaluating early versus late outcomes there’s going to be the need for
some ﬂexibility because if you’re looking at trials of early patency for ﬁstulas that by their nature are not going to be used for a
number of months it may not be practical to have what I would love to see, which is a truly pragmatic measure, something along
the lines of a ﬁstula is functional if and only if it can be used for the purpose for which it was made…” -H4
• “For a pragmatic trial a deﬁnition that is more real world is ﬁne. But for a more regulated trial then you need something that is FDA
approved or whatever and so maybe we should be agreeing that it should be an adequate HD and then decide, depending on the
kind of trial that you’re doing, you have to have ﬂexibility. One size will not ﬁt all trials.” -H4
Theme: Ensuring Robustness and Validity
Responsiveness to changes over time
• “Responsiveness is important. When we’re taking care of our patients and the vascular access is worse, and we look at the blood
ﬂow and it can only go to 200 mL/min, there’s a very big chance that ﬁstula is failing.” -H5
Reliability of the outcome measure
• “The only time it (the access blood ﬂow) changes it’s a bad stick or a bad cannulation or I’m moving around.” -P4
• “I have an issue with ﬂow, because it depends how the needles go in. It’s not reproducible, it’s not reliable; it’s different for
different people.” -H5
• “Right, and I don’t agree with the blood ﬂow thing either. Because I can go and have one blood ﬂow on Monday, and not get a
good blood ﬂow on Wednesday, and go back on Friday. And I don’t agree with the Kt/V either, only because of the fact that you
can drop so much and still get enough clearance that you’re okay.” -P5
Theme: Integrating Patients’ Values and Preferences
Meaningful and important to patients
• “Let me ask you; do you care more about how much blood is ﬂowing through that based on our machine measurement?
Or how many times you have to go get a procedure done? Which one of those things really matter?” -H2 “Those doggone
procedures…” -P2
• “We do measure function in a whole pile of different ways. Time to revision, their primary patency, delayed assisted primary, all the
various technique deﬁnitions. But the most important thing, from a patient’s point of view is how long you actually go without
having to do anything with it. Uninterrupted dialysis where you haven’t had to revise, you haven’t had to de-clot it. That’s the most
important thing.” -H5
• “What is the most meaningful and important to you when having those discussions about treatment?” -H4 “Time period between
interventions.” -P4
(Continued)
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Access Core Outcome Measure in Hemodialysis
Informed by shared decision making
• “We have a combined clinician/patient reported outcome; the patient is reporting that their access is ﬁne, the clinician is reporting
that the access is ﬁne.” -H4
• “Even if the blood ﬂow rate has decreased, but if the doctors and the patient agreed to not do intervention but increase the time
so that the clearance is better and still avoid hospitalization or intervention that would be a good outcome too. If the patient does
not want to increase their time then having an intervention would be ﬁne” -H4
• “…At that trial end point there is a collaborative decision between the physician and the patients about whether during that period
of time and during the period that the intervention has been given they agree that the ﬁstula functioned or not and as a clinician/
patient reported outcome.” -H4
• “The prescription is a matter of practice between the physician and the patient…we shouldn’t judge what’s in that prescription.”
-H1
Abbreviations: C, caregiver; H, health professional; P, patient; PL, plenary (summary from individual breakout discussion groups); number indicated (eg, H1) refers to the
Group ID (1-5).
Special Reportsuggested that cannulation problems could be a core
outcome specifically for trials of arteriovenous access.
Multidisciplinary Involvement
The involvement of a multidisciplinary team in establishing
and maintaining a functioning access was identified as
another reason for prioritizing function as the core
outcome. An outcome that captured the result of a multi-
disciplinary team effort, such as the process and quality of
care of patients requiring HD, was expected to provide
valuable information beyond the effect of an intervention.
As one health professional observed, “It’s not just theTable 1. Proposed Outcome Measures for Function
Proposed Outcome
Measure Advantages D
Uninterrupted use of the
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Ability to receive the
prescribed dialysis
Simple; feasible across
different settings and
internationally; inexpensive;
pragmatic
S
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u
694surgeon that puts it in. It’s not just the patient. It’s the entire
team. It’s the doctor, it’s the nurse, it’s the technician; it’s
everybody that’s involved with that patient’s care. So I want
to make sure our prime measure gives us a chance to look at
the entire team that’s taking care of that patient.”
Contributing to Quality of Life
There was general agreement that a functioning access
enables adequate HD that in turn affects patients’ quality of
life. Participants drew a distinction between “maintenance
of life” versus “quality of life” because a malfunctioning
access may maintain life, but have a detrimental impact onisadvantages
Proposed Metric(s)/
Method of Aggregation
tandardization of
ndication for
nterventions
Time to event (ﬁrst/next
procedure); rate
xpensive; may not be
vailable across different
ettings/internationally;
imited reliability; prone to
easurement errors; not
atient-centered; time
onsuming; standardization
f measurement challenging
expertise, equipment)
Percentage change
over a speciﬁc time period
-needle cannulation not
pplicable to catheters;
tandardization of indication
or interventions;
tandardization of what the
rescribed dose should be
o be considered “adequate
ialysis”
Proportion of times
within a month
tandardization of what the
rescribed dose should be to
e considered “adequate
ialysis”; does not capture “at
hat price” (ie, need for
nterventions) the access is
sable for dialysis
Proportion of times
within a month; time
to event
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Box 2. Workshop Recommendations for Selecting, Deﬁning,
and Implementing a Core Outcome Measure for Hemodialysis
Vascular Access
Reasons for selecting function as the core outcome for
vascular access
• Relevant to all vascular access types
• Reﬂects the most important aspect of a vascular access (eg,
vascular access as the “life line”)
• Critical for clinical decision making and quality improvement
in vascular access care
• Impacts on patient’s overall well-being
• Reﬂects the result of a multidisciplinary effort
• Captures a broad range of inter-related important outcomes
and complications (eg, cannulation problems, dialysis ade-
quacy, pain, procedures)
A core outcome measure for function
• Should be meaningful and important to patients
• Requires a pragmatic deﬁnition
• May be based on shared decision making between patient
and treating team (eg, threshold to intervene on an access,
deﬁnition for dialysis prescription)
• Should be established routine clinical practice across
different settings and countries
• Should not be cumbersome or expensive to measure
• Should not require additional equipment or training (eg, to
measure access ﬂow)
• Has to be reliable and responsive with content validity
• Should include the need for interventions, uninterrupted
dialysis, and achievement of prescribed dialysis
Implementation of a core outcome measure requires
• To be simple and feasible
• Clear instructions on how to operationalize the outcome
measure in clinical practice
• Endorsement by trial registries (such as ClinicalTrials.gov)
and by journals in their instructions to authors
• Engagement of individual trial groups, societies, the Interna-
tional Committee of Medical Journal Editors, and renal
registries
• Support and endorsement from regulatory agencies and
industry
• Dissemination of incentives associated with the use of
standardized outcome measures (ie, improve quality of
comparative research, and facilitate trial registration, quality
improvement, and clinical decision making)
Special Reportquality of life due to the need for recurrent interventions
and interruption of treatments.
Capturing Important Multidimensional Aspects
Function incorporated various important impacts on health,
well-being, and quality of care. For example, problems with
access function could interfere with daily life due to extra
hospital visits for necessary corrective or maintenance pro-
cedures or for alternate access creation/insertion in case of
access failure. Given the potential overlap of function with
other outcomes, investigators conducting trialswith a specific
focus on access function may elect to untangle the multidi-
mensionality of access function by measuring contributingAJKD Vol 71 | Iss 5 | May 2018outcomes separately (ie, type of interventions, needling
problems, access replacement, dialysis adequacy, etc).
Preventing Subsequent Consequences
Some participants considered function as a “fundamental
outcome” that triggered a cascading effect on other outcomes;
for instance, as one patient described, “if it (the access) doesn’t
function properly you’re in pain and then you have to go get it
redone again and you have to have that catheter stuck back in
you and then you run the risk of infection with a catheter in.”
An intervention that improved the function of a vascular access
would therefore prevent further potential complications.
Emphasizing Experiential Relevance and Severity
Variability in Experiences
Some patients emphasized the importance of cannulation
problems, particularly if they had experienced a compli-
cation. On the other hand, participants acknowledged that
some outcomes could be regarded to be less important if
patients had not experienced the outcome (eg, severe steal
syndrome). However, function was recognized as the most
important outcome by all stakeholders and could be
comprehended by all patients.
Fear-Driven Prioritization
Fear and anxiety were identified as main drivers for priori-
tizing outcomes involving invasive and severe complications,
such as needling problems, aneurysms, or infection. In the
interim survey results, the only outcome thatwas ratedhigher
by patients/caregivers than by health professionals was
aneurysm/pseudoaneurysm, and workshop participants
suggested that the fear of potentially life-threatening bleeding
complications may explain this difference.
Demonstrating Feasibility of Implementation
Simple, Requiring Minimal Resources
For an outcome measure to be implemented across all
HD trials, “it needed to be easy to measure, readily imple-
mented in everyday practice, and for the purpose of quality
improvement, and something that wouldn’t be a burden on
investigators, and could very easily be measured during
studies” (plenary discussion, group 2). Participants supported
a simple definition such as “ability to use the access for dialysis
without the need for interventions” or “ability to receive the
prescribed dialysis.” While a physician suggested access blood
flow to be “easily measurable, everyone understands it, and
you can track it very easily,” patients and themajority of health
professionals thought it may be complicated and cumbersome
to measure, costly, unreliable, and difficult to interpret.
Pragmatic Deﬁnition
Participants supported a pragmatic definition for the core
outcome that was not too detailed and would be applicable
to different practice settings and access types. A pragmatic
definition was expected to capture real-world practice pat-
terns by allowing clinicians and patients to decide whether
the conditions of the outcome measure, such as “prescribed695
Special Reportdialysis,” were fulfilled. However, some were concerned
that using a pragmatic definition would consequently result
in inconsistencies in how the outcome was measured. As
voiced by a health professional, “But you will see a different
doctor the next day who might make a different recom-
mendation, and that’s what worries me, inconsistency.”
Participants concluded that, in the words of a health pro-
fessional, “the definition should be clear, so that even
though the concept is simple, everybody interprets it the
same way.” A proposed solution to overcome the risk for
inconsistency in outcome reporting was to provide a “tick
box” with stepwise instructions on how to collect data for
the core outcome because, as expressed by a health pro-
fessional, “as everybody knows the devil is in the detail
when it comes down to actually measuring it.”
Practicality Across Settings Internationally
Participants remarked on the challenges arising from dif-
ferences in practices and available resources across different
countries, cultures, and practice settings. They considered
the variability in using an outcome measure for function,
such as “the ability to receive adequate dialysis without the
need for interventions,” as the threshold to intervene on an
access, may differ between patients and clinicians, andmore
broadly across centers and regions. “Across cultures, we do
consider adequate dialysis differently,” observed a health
professional, “By leaving it at the prescribed dialysis, you
leave it up to the actual center or country.” Thus, differences
in defining sufficient flow rates, dialysis adequacy, or
indication for access intervention could be defined locally to
allow for differences in practice and global implementation.
Flexibility for Different Trial Settings
Some participants mentioned that there should be some
flexibility to the outcome measure for it to be applicable to
different trial settings, such as real-life pragmatic trials
versus more regulated explanatory trials and trials of short-
versus long-term follow-up duration because, as expressed
by a health professional, “one size will not fit all trials.” For
example, “ability to use the access for HD” as an outcome
measure for function may not be applicable to trials that
investigated the short-term outcomes of a surgical proced-
ure 1 month after fistula creation because the fistula is not
expected to be usable for dialysis at that time. Participants
argued that a trial with follow-up that was too short to assess
the function of an access may not address outcomes that are
relevant to clinicians and patients. Suggested solutions
included sufficient flexibility in the outcomemeasure to suit
different trial settings or a paradigm shift to promote
outcome measures that really matter, as voiced by a health
professional: “…regardless of ultrasound flow at 1 month,
it’s whether they [the accesses] work ultimately.”
Ensuring Robustness and Validity
Responsiveness to Changes Over Time
To show the potential efficacy of an intervention, it was
considered important for the outcome measure to be696responsive to changes over time. Otherwise, a favorable
effect on the vascular access could be missed. While the
majority of participants considered “the need for in-
terventions” a sensitive and meaningful measure of change
in access function, others argued that “access blood flow”
measures may be more responsive to change over time.
Reliability of the Outcome Measure
Participants questioned the reliability of access blood flow
recordings as a measure of access function because flow
rates could be decreased due to malpositioning of the
dialysis needles or hemodynamic changes rather than a
true access-related problem (eg, thrombosis or stenosis).
Similarly, the reliability of surrogate markers of adequate
dialysis were challenged. As one patient explained, “I don’t
agree with the blood flow thing either because I can go
and have one blood flow on Monday, and not get a good
blood flow on Wednesday, and go back on Friday. And I
don’t agree with the Kt/V either, only because of the fact
that you can drop so much and still get enough clearance
that you’re okay.”
Integrating Patients’ Values and Preferences
Meaningful and Important to Patients
Access function meant the ability to undergo uninter-
rupted dialysis without the need for access procedures,
which was critically important for patients and caregivers.
In comparison, access flow and surrogate measures of
dialysis adequacy such as Kt/V were considered less rele-
vant. Some patients described their access function by the
number of interventions or the time frame they were able
to dialyze without the need for procedures, highlighting
the importance of access procedures (ie, angioplasty,
thrombectomy, revision, or access replacement) to define
access function. Defining an outcome measure that was
meaningful to all end-users was expected to enhance the
broad engagement of clinicians and patients and global
implementation of the core outcome across different
clinical and research settings.
Informed by Shared Decision Making
There was detailed discussion about how to further define
specific terms used to describe access function, such as the
ability to receive “prescribed” dialysis without the “need
for interventions.” “The prescription is a matter of practice
between the physician and the patient,” argued one health
professional; this attitude was also expressed by another
health professional, “…even if the blood flow rate has
decreased, but if the doctors and the patient agreed to not
do an intervention, but increase the [dialysis] time so that
the clearance is better and still avoid hospitalization or
intervention that would be a good outcome too. It comes
down to if the patient does not want to increase their time
then having an intervention would be fine.” It was rec-
ommended that the definition should be based on shared
decision making between patients and clinicians because
one size does not fit all.AJKD Vol 71 | Iss 5 | May 2018
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Access function is highly relevant, important, and appropriate
as the core outcome for vascular access because of its appli-
cability to all access types, impact on quality of life and sur-
vival of patients, and representation of a multidisciplinary
team effort. It encapsulates other important aspects of a
vascular access, such as the ability to cannulate and receive
adequate dialysis, and has implications on potential compli-
cations, such as pain, hospitalization for access procedures, or
access replacement. Other important outcomes, such as
infection, steal syndrome, aneurysms, and cannulation
problems, were deemed unsuitable as core outcomes given
their restricted applicability to specific access types or fear-
and/or experience-driven prioritization. Althoughworkshop
participants supported an outcomemeasure that is simple and
applicable across different clinical and trial settings, concerns
were raised about inconsistent interpretation, reproduc-
ibility, and applicability to trials of short duration (Table 1).
To address the concerns of inconsistencies in defining
access function, a pragmatic “patient-clinician–reported”
outcome was suggested that would be based on the shared
decision making between clinicians and patients, which
takes into account differences in clinical practice within
units and across countries and cultures. For trials with
follow-up that is too short to measure a core outcome, such
as access function, participants argued that in the context of
clinical decision making, patients and clinicians want to
know whether an intervention affects outcomes that they
consider important and meaningful and as such, one should
question the usefulness of trials of very limited duration.
The increasing popularity of pragmatic clinical trials and
registry-based randomized clinical trials may further over-
come the concern of short follow-up times.30-34
Workshop participants and contributors strongly sup-
ported an outcome measure that is relevant and meaningful
to patients with end-stage kidney disease to ensure that
research in this area addresses outcomes that matter to those
who are ultimately affected and in need of HD. Patients
advocated for function to be measured as the ability to
receive uninterrupted and adequate dialysis without the
need for interventions rather than using surrogate markers,
such as access blood flow or Kt/V. It was considered
important to involve patients as partners during all stages in
developing core outcome measures, which is in line with
recent recommendations from Outcome Measures in
Rheumatology (OMERACT).35 The Dialysis Vascular Access
group of the American Society of Nephrology KidneyHealth
Initiative recently released recommendations for standard-
ized clinical trial end points tailored to the different types of
vascular access and time points of their life cycle. The SONG-
HD Vascular Access Initiative complements this project by
identifying a core outcome measure for vascular access that
is meaningful to patients and clinicians and feasible to be
reported consistently across all trials in HD.18-20
Recommendations from this workshop reflect the
consensus of a broad range of international stakeholders,AJKD Vol 71 | Iss 5 | May 2018including patients and caregivers. We acknowledge that
most participants were from high-income countries and
only patients residing locally in Chicago could participate
due to limited resources to support travel. However,
similar perspectives have been documented among pa-
tients in other countries,11,36,37 suggesting that our find-
ings are broadly transferable.
Specific outcome measures that were proposed and dis-
cussed during the workshop (Table 1) will now be assessed,
taking into consideration establishedmeasurement properties
and feasibility aspects,29 and a core outcome measure for
access function will be selected and piloted in different clin-
ical settings to ensure that it fulfils the OMERACT criteria of
discrimination (responsiveness to change and reliability),
truth (validity), and feasilbility23 and implemented pro-
spectively in clinical trials. The recommendations from this
workshop (Box 2) will be integrated into the finalization of
the core outcomemeasure for HD vascular access and should
facilitate better understanding, endorsement, and imple-
mentation of core outcomemeasures into HD trials and other
forms of research. Currently, vascular access outcomes are
reported in more than 1,400 different ways.38 Reporting
vascular access function consistently across trials will improve
comparison of the effectiveness of interventions across trials,
provide information on the performance of vascular access
function in different clinical settings, and deliver a useful
quality improvement tool. Ultimately thismay strengthen the
value of trials for decision making based on vascular access
function, an outcome that is critically important and relevant
to patients, caregivers, and health professionals. We believe
that core outcomes for HD that are important to patients and
clinicians will optimize shared decision making and ulti-
mately lead to better patient outcomes.Supplementary Material
Item S1: Facilitator question guide for breakout discussion.
Table S1: SONG-HD Vascular Access Workshop Investigators.
Table S2: Breakout groups that contributed to the respective
themes.
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